anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To produce a readily producible incense stick for ignition convenient for igniting an article requiring the ignition such as fireworks and suitable for ignition by molding a material consisting essentially of wood flour, a firing metallic powder and a celluloid component, drying the molded material and forming the incense stick. SOLUTION: This incense stick 1 for ignition is obtained by adding a wood flour and a firing metallic powder 3 to a celluloid solution prepared by predissolving a celluloid component in acetone, kneading the mixture, molding the kneaded material 2 and drying the resultant molded material. Furthermore, the incense stick 1 for ignition is obtained by adding 35-40 pts.wt. wood flour which is a combustion component and 4-10 pts.wt. firing metallic powder 3 having actions on a raise in ignition temperature and improvement in ignitability to the celluloid solution prepared by predissolving 29-50 pts.wt. celluloid component in acetone of the same 29-50 pts.wt., kneading the resultant mixture, molding the kneaded material 2 into a prescribed shape such as a rodlike one and drying the molded material at normal temperature or a temperature without causing the ignition. For example, 25 pts.wt. wood flour having 90 mesh size, 3 pts.wt. firing metallic powder 3, 20 pts.wt. celluloid and 20 pts.wt. acetone are prepared and the total amount of the wood flour and firing metallic powder 3 is placed in the celluloid solution. The resultant mixture is kneaded to afford the kneaded material 2, which is then molded and dried in order to afford the incense stick 1 for ignition.
A major focus of HIV- 1 vaccine research is to design an immunogen that can elicit potent broadly neutralizing antibodies (bnAbs) to the envelope glycoproteins (Env). A clade C Env is disclosed that is stable and efficiently cleaved on the cell surface. Soluble forms of the Env are also disclosed. This Env exposes epitopes for many broadly neutralizing antibodies targeting distinct regions of the Env, while occludes those of non-neutralizing antibodies. Binding of several conformation dependent antibodies suggests that the Env assumes a native conformation on the cell surface and in soluble form. The efficient cleavage and antibody binding properties of the Env makes it a suitable immunogen to use in a vaccine and to serve as an effective platform for rational design of HIV- 1 vaccine immunogens.
Cohort 1 will consist of 2 age groups (6 to \< 12 years and 12 to \< 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.
Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
A PECS block of 0.25 % bupivacaine with epinephrine 1:200000 (below the toxic dose limit of 3 mg/kg) in divided doses to cover the fascial planes identified in PECS I and PECS II. At the completion of surgery, the wound will be infiltrated with up to 0.2 ml/kg of 0.25 % bupivacaine into the wound.
The invention relates to a tree-like polymer nanometer drug delivery carrier targeting doxorubicin. The structural general formula of the targeting doxorubicin is PEG-b-PAMAM-hydrozone-(DOX)n. A tree-like polymer nanometer drug delivery carrier targeting doxorubicin of liquid tumors representative to myeloma is provided in the invention. The acidic environment (pH of 5.5) of myeloma makes a hydrogen bond connecting a carrier with doxorubicin be broken, so complete doxorubicin molecules are released. The release is only carried out under the acidic condition of the myeloma, so the treatment pertinence of the drug is greatly improved. P-glycoprotein will diffuse to doxorubicin monomer elimination cells in cells, so tumor cells generate multiple drug resistances. The carrier drug can avoid the medicine efflux phenomenon caused by the p-glycoprotein and can also avoid the multiple drug resistances.
PURPOSE OF REVIEW: Combined pulmonary fibrosis and emphysema (CPFE) is a syndrome characterized by upper lobe emphysema with lower lobe fibrosis. We aim to bring some clarity about its definition, nature, pathophysiology, and clinical implications.
RECENT FINDINGS: Although multiple genetic and molecular pathways have been implicated in the development of CPFE, smoking is considered the most prevalent risk factor. CPFE is most prevalent in middle-aged men with more than 40 pack-years of smoking and can be seen in about 8% of all chronic obstructive pulmonary disease (COPD) patients. Given its nature, it is a radiological diagnosis, better defined by computed tomography (CT). Spirometry can be normal despite severe disease or can have restrictive or obstructive patterns, but the diffusing capacity of the lungs (DLCO) is consistently low regardless of the spirometry pattern. The disease is progressive, with high occurrences of lung cancer and pulmonary hypertension, complications that limit survival. Unfortunately, there is no treatment found to be beneficial other than supportive care and guideline-directed medical therapy.
SUMMARY: CPFE is best described as a clinical and radiological syndrome where smokers are particularly at greater risk. Although simplistic, the earliest definition based chiefly on radiographic findings can identify a patient population with similar physiology. The most recent consensus proposes the definition based on mainly radiological findings with impaired gas exchange.
This review explores the pivotal role of angiogenesis in breast cancer progression and treatment. It covers biomarkers, imaging techniques, therapeutic approaches, resistance mechanisms, and clinical implications. Key topics include Vascular Endothelial Growth Factors, angiopoietins, microRNA signatures, and circulating endothelial cells as biomarkers, along with Magnetic Resonance Imaging, Computed Tomography Angiography, Ultrasound, and Positron Emission Tomography for imaging. Therapeutic strategies targeting VEGF, tyrosine kinase inhibitors, and the intersection of angiogenesis with immunotherapy are discussed. Challenges such as resistance mechanisms and personalized medicine approaches are addressed. Clinical implications, prognostic value, and the future direction of angiogenesis-targeted therapies are highlighted. The article concludes with reflections on the transformative potential of understanding angiogenesis.
In the U.S., 8.37 million adults over 65 will experience a hospital stay over the next year, which often has serious and long-lasting consequences including profound deterioration in physical function. Following a hospital stay, around 1.35 million patients with deconditioning require rehabilitation in a skilled nursing facility (SNF) each year to address the deleterious musculoskeletal and functional deficits from deconditioning. More than 64% of patients discharge from SNFs at functional levels that predispose them to adverse events, including rehospitalization, failing health, disability, institutionalization, or death. Physical function is a known modifiable predictor of these deleterious events, which can be addressed with rehabilitation. Therefore, more progressive and targeted musculoskeletal rehabilitation strategies that optimize physical function more effectively are needed.

Therefore, the purpose of this study is to determine the effectiveness of a high-intensity rehabilitation approach (also referred to as i-STRONGER) at multiple skilled nursing facilities (SNFs), while evaluating characteristics of successful implementation through a rigorous, pragmatic cluster randomized controlled trial (16 Intervention SNFs vs 16 Usual Care SNFs). The investigators will promote high-intensity rehabilitation delivery to patients in an effort to address poor physical function outcomes. Specifically, the investigators will train rehabilitation clinicians at Intervention sites using distance-based instruction and collect study outcomes via the electronic medical record. Additionally, the investigators will gather quantitative and qualitative data (mixed methods) to evaluate processes, clinician-specific characteristics, and facility-specific contexts of implementation. The study methods seek to maximize successful reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) across Intervention sites. The implementation strategy is informed by the RE-AIM framework and integrated with educational and behavioral theories to facilitate clinical adoption of high-intensity rehabilitation.
BACKGROUND: Effective discrimination of lung adenocarcinoma (LUAD) in situ (AIS) from benign pulmonary nodules (BPN) is critical for the early diagnosis of AIS. Our pilot study in a small cohort of 90 serum samples has shown that serum interleukin 6 (IL-6) detection can distinguish AIS from BPN and health controls (HC). In this study, we intend to comprehensively define the diagnostic value of individual and combined detection of serum IL-6 related to the traditional tumor markers carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) for AIS.
METHODS: The diagnostic performance of serum IL-6 along with CEA and CYFRA21-1 were evaluated in a large cohort of 300 serum samples by a chemiluminescence immunoassay and an electrochemiluminescence immunoassay. A training set comprised of 65 AIS, 65 BPN, and 65 HC samples was used to develop the predictive model for AIS. Data obtained from an independent validation set was applied to evaluate and validate the predictive model.
RESULTS: In the training set, the levels of serum IL-6 and CEA in the AIS group were significantly higher than those in the BPN/HC group (P < 0.05). There was no significant difference in serum CYFRA21-1 levels between the AIS group and the BPN/HC group (P> 0.05). Serum IL-6 and CEA levels for AIS patients showed an area under the curve (AUC) of 0.622 with 23.1% sensitivity at 90.7% specificity, and an AUC of 0.672 with 24.6% sensitivity at 97.6% specificity, respectively. The combination of serum IL-6 and CEA presented an AUC of 0.739, with 60.0% sensitivity at 95.4% specificity. The combination of serum IL-6 and CEA showed an AUC of 0.767 for AIS patients, with 57.1% sensitivity at 91.4% specificity in the validation set.
CONCLUSIONS: IL-6 shows potential as a prospective serum biomarker for the diagnosis of AIS, and the combination of serum IL-6 with CEA may contribute to increased accuracy in AIS diagnosis. However, it is worth noting that further research is still necessary to validate and optimize the diagnostic efficacy of these biomarkers and to address potential sensitivity limitations.
Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
INTRODUCTION: Daratumumab is a humanized IgG1 kappa monoclonal antibody directed against CD38 used to treat myeloma. The recommended dose of daratumumab is 16 mg/kg, with no lower or upper threshold. Here, we present the first split-dose daratumumab infusion experience in a myeloma patient with morbid obesity in whom daratumumab was interrupted because of grade 3 infusion-related reaction.
CASE REPORT: A female myeloma patient with morbid obesity received a combination of chemotherapy with daratumumab because of disease relapse. The calculated dose for the first intravenous daratumumab infusion was 1840 mg/day based on the weight of the patient, which was measured as 115 kilograms. Daratumumab infusion was initiated as appropriate but needed to be stopped because of a severe sudden presentation of shortness of breath and hypoxemia.
MANAGEMENT AND OUTCOME: After daratumumab was stopped, premedication was repeated, and oxygen, intravenous and inhaler steroids, inhaler β2 agonists and intravenous diphenhydramine were given in repeated doses. She was monitored and followed up in the emergency critical care unit. Daratumumab treatment with a split-dose schedule was planned after she fully recovered from all signs and symptoms. The total dose was divided into two doses and was given without any complications on two consecutive days. After that, she was also able to tolerate once a week 1840 mg of daratumumab in a single day.
DISCUSSION: There is a paucity of data regarding the best practice for instituting intravenous daratumumab in patients with morbid obesity regarding the infusion rate and duration, optimal dosing, and ideal way to cope with infusion-related reactions. Our case suggests a potential role for a split-dose schedule for patients with obesity and potential dose reductions and infusion-related reactions.
The invention relates to a technique for activating an in vivo immune function by promoting IFN-Ϝ production using a bifidobacterium-fermented product of a Brassica plant and a technique for preventing or improving a disease caused by candida infection, for example, an allergic disease such as atopic dermatitis, candidiasis such as periodontal disease, dental caries, stomatitis, glossitis, oral infection, aspiration pneumonia or vaginitis. More particularly, it relates to an agent for preventing or improving a disease caused by candida infection containing a bifidobacterium-fermented product of at least one kind of plant selected from the group consisting of Brassica plants and carrot, an oral composition for preventing or improving a disease caused by candida infection, an immunostimulant and the like. Examples of the bifidobacterum include Bifidobacterum longum and the like. Examples of the plant which is at least one kind of plant selected from the group consisting of Brassica plants and carrot include broccoli, cabbage, kale, cauliflower, Brassica juncea var. integlifolia, oilseed rape, brown mustard, radish, radish leaves, Brassica rapa var. hakabura, Brassica rapa var. peruviridis and the like.
Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
Donepezil hydrochloride is a reversible inhibitor of the enzyme acetylcholinesterase, known chemically as (±)-2, 3-dihydro-5, 6-dimethoxy2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one hydrochloride. Donepezil hydrochloride is commonly referred to in the pharmacological literature as E2020. It has an molecular formula of C24H29NO3HCl •H2O and a molecular weight of 433.95. Donepezil hydrochloride USP (monohydrate) is a off-white to white crystalline powder and is soluble in chloroform.

Donepezil hydrochloride USP (monohydrate) is available for oral administration in film-coated tablets containing 5 or 10 mg of donepezil hydrochloride. 

Inactive ingredients are hydroxypropyl cellulose, lactose monohydrate, low substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, pregelatinized starch. The film coating contains hypromellose, polyethylene glycol and titanium dioxide. Additionally, the 10 mg tablet contains yellow iron oxide (synthetic) as a coloring agent. 

USP test procedures for Organic Impurities pending.
The invention provides a traceable boric acid nano-drug compound and a preparation method thereof. In an organic solution, mixing the boric acid drugs and natural polyphenol, and mixing the obtained product with iron ions to obtain the boric acid anticancer nano-drug compound containing the boric acid drugs, the natural polyphenol and the iron ions. The traceable boric acid nano-drug compound can be used for tumor tracing and the like. The invention also provides the application of the nano-drug compound in the preparation of drugs for preventing and/or treating tumors and inflammatory diseases. The nano-drug compound also has tracing capability, and can ensure that the anticancer drug only acts on tumor sites, thereby reducing side effects, and having better biocompatibility and better treatment efficiency. The invention has simple and safe synthesis, can efficiently and safely deliver the boric acid drug and has excellent medical value.
Patients in group 1 underwent catheterization of the lumbar plexus from the posterior access on admission to the hospital and began analgesia with bupivacaine 0.125% 6-8 ml / h. Intraoperative anaesthesia was provided with a bupivacaine bolus of 0.5% 200 mg in a lumbar catheter and a sciatic nerve block with 1.5% 450 mg of lidocaine. Postoperative analgesia was provided by an elongated lumbar plexus block with bupivacaine 0.125% 6-8 ml / h.
FIELD: veterinary science, agriculture. SUBSTANCE: invention relates to production of vaccines used for an intramuscular immunization of agriculture animals against Aujeszky's disease. Vaccine is prepared by using the strain MK-25. The strain is grown in transplanted cultures of piglet or Asiatic ibex kidney cells. Obtained suspension of virus is mixed with stabilizing medium. Stabilizing medium has peptone and lactose. Vaccine is poured into ampoules and lyophilized. Activity of obtained vaccine is 10 6,75 -10 7,25  TCD 50 /ml. After a single immunization vaccine induces the expressing immunity in 100% of agriculture animals. EFFECT: enhanced effectiveness of immunization. 1 tbl, 2 ex
A medicinal composition has been created that is useful in the treatment of PMS in human females who experience adverse PMS symptoms. The composition is comprised of an extract of asparagus racemosus. The composition preferably includes about eighty-five parts Asparagus racemosus and about five parts each of Withania sominifera, Pedalium murex, and Tinospora cordifolia. The active component of the Asparagus racemosus is saponin glucoside (A4). Preferably, the composition is administered in capsular form with each capsule containing about one-half gram of the composition. Two of these capsules are taken three times a day.
Memory persistence is a double edge sword. Persistence of adaptive memories is essential for survival and even determines who we are. Neurodegenerative conditions with significant memory loss such as Alzheimer's disease, testify how defects of memory persistence have severe and irreversible effects on personality, among other symptoms. Yet, maintenance of overly strong maladaptive memories underlies highly debilitating psychiatric conditions including post-traumatic stress disorder, specific phobia, substance dependence and binge eating disorder. Here we review the neurobiological mechanisms supporting memory formation, persistence, inhibition and forgetting. We then shift the focus to how such mechanisms have been exploited to alter the persistence of laboratory-generated memories in human healthy volunteers as a proof of concept. Finally, we review the effect of behavioural and pharmacological interventions in anxiety and addiction disorder patients, highlighting key findings, gaps, and future directions for basic and translational research.
FIELD: medicine. SUBSTANCE: method involves applying complex anti-alcohol therapy program including reflex zone stimulation, medicamentous therapy and psychotherapy. Homeopathic treatment is introduced into the program. Proproten 100, Nux vomica C6 and Acidum sulfuricum C6 are applied within the first 7-8 days at a dose of 5 grains twice a day. Then, Syphilinum 200 C preparation is administered during the next 7-8 days at a dose of 7 grains once a day, Quercus 30 C at a dose of 5 grains 3 times a day and Nux vomica 3 C at a dose of 5 grains 3 times a day. Nux vomica 3 C is given at a dose of 5 grains 3 times a day during the following 12-13 days. Constitutional preparation is administered during the next 30 days in C30 dilution with Nux vomica 6 C at a dose of 7 grains once a day and postrehabilitation Proproten 100 administration at a dose of 7 grains once a day in three courses. The latter is taken during one month with one month long pause following. Nux vomica 6 C is administered at a dose of 7 grains once a day in four courses with one month taking the preparation and one month long pause. The constitutional preparation is taken in 200-100:1 dilutions at a dose of 5 grains once each second day during three month. Phytotherapy course involves taking decoctions prepared with Asarum root, lamb succory, Salix, bearberry, wormwood, thyme, Origanum, mistletoe, Leonorus, valerian, German camomile, passion flora. Baths are taken with St. John's wort, ginseng root, calendula, pepper mint decoctions added. Psychomuscular training is applied involving psychic and muscular relaxation assuming postures and respiratory exercises like tree, shavasana, anuloma-viloma, organism vitalization, meditation according to Yoga and Chinese Ci-gong system. Self-analysis verbalization exercises are introduced into psychotherapy course under physician control. Rehabilitation stages are not less than 60 days long. Certain schedule is to be followed. The first two days are spent in building suggestion for rehabilitation. Reflex therapy is applied from the second to eighth day, homeopathy from the second to the sixtieth day. General phytotherapy is applied from the eighth to fifty ninth day, psychomuscular training is applied from the thirty ninth to the fifty ninth day, respiratory exercises are administered from the thirty ninth to the fifty ninth day, psychotherapy from the fifty fifth to the fifty ninth day, sober life mode suggestion is applied at the sixtieth day. EFFECT: enhanced effectiveness of treatment course. 1 dwg
BACKGROUND: Oral Potentially Malignant Disorders (OPMDs) refer to a heterogenous group of clinical presentations with heightened rate of malignant transformation. Identification of risk levels in OPMDs is crucial to determine the need for active intervention in high-risk patients and routine follow-up in low-risk ones. Machine learning models has shown tremendous potential in several areas of dentistry that strongly suggest its application to estimate rate of malignant transformation of precancerous lesions.
METHODS: A comprehensive literature search was performed on Pubmed/MEDLINE, Web of Science, Scopus, Embase, Cochrane Library database to identify articles including machine learning models and algorithms to predict malignant transformation in OPMDs. Relevant bibliographic data, study characteristics, and outcomes were extracted for eligible studies. Quality of the included studies was assessed through the IJMEDI checklist.
RESULTS: Fifteen articles were found suitable for the review as per the PECOS criteria. Amongst all studies, highest sensitivity (100%) was recorded for U-net architecture, Peaks Random forest model, and Partial least squares discriminant analysis (PLSDA). Highest specificity (100%) was noted for PLSDA. Range of overall accuracy in risk prediction was between 95.4% and 74%.
CONCLUSION: Machine learning proved to be a viable tool in risk prediction, demonstrating heightened sensitivity, automation, and improved accuracy for predicting transformation of OPMDs. It presents an effective approach for incorporating multiple variables to monitor the progression of OPMDs and predict their malignant potential. However, its sensitivity to dataset characteristics necessitates the optimization of input parameters to maximize the efficiency of the classifiers.